Teva Pharmaceutical Industries Ltd. $TEVA Holdings Boosted by Public Sector Pension Investment Board

Public Sector Pension Investment Board grew its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 11.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 670,467 shares of the company’s stock after purchasing an additional 69,000 shares during the quarter. Public Sector Pension Investment Board owned approximately 0.06% of Teva Pharmaceutical Industries worth $13,543,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in TEVA. Howard Bailey Securities LLC grew its stake in Teva Pharmaceutical Industries by 3.5% during the 3rd quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock worth $292,000 after buying an additional 494 shares during the last quarter. ASR Vermogensbeheer N.V. lifted its position in Teva Pharmaceutical Industries by 1.6% in the 3rd quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after purchasing an additional 515 shares during the last quarter. Retirement Planning Co of New England Inc. boosted its stake in Teva Pharmaceutical Industries by 1.8% during the 3rd quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock valued at $671,000 after purchasing an additional 588 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Teva Pharmaceutical Industries by 0.5% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock worth $1,981,000 after purchasing an additional 615 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 6.1% in the third quarter. Smartleaf Asset Management LLC now owns 10,794 shares of the company’s stock valued at $207,000 after purchasing an additional 624 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on TEVA shares. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, December 22nd. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Scotiabank increased their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.11.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the sale, the vice president directly owned 48,384 shares of the company’s stock, valued at $1,387,653.12. This trade represents a 70.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at approximately $170,630. This represents a 68.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 422,060 shares of company stock worth $12,254,965. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Trading Up 0.1%

Shares of TEVA stock opened at $33.96 on Monday. The stock has a 50-day simple moving average of $32.08 and a 200 day simple moving average of $24.54. The stock has a market capitalization of $39.05 billion, a P/E ratio of 28.30, a P/E/G ratio of 1.94 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. Teva Pharmaceutical Industries’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.